Objective We herein conducted a retrospective study to evaluate the long-term efficacy and safety of sitagliptin treatment in elderly patients with type 2 diabetes mellitus. Methods We analyzed the changes in glycemic control in 112 Japanese type 2 diabetes patients over 65 years of age treated with 50 mg/day sitagliptin. Hemoglobin A1c (HbA1c) levels, liver and kidney functions, and usage of hypoglycemic agents were recorded for 24 months. Results HbA1c levels were significantly decreased, and the significance of HbA1c reduction was maintained during the observation period [from 7.7 1.1% to 7.2 0.7% (p<0.001) at the end of observational period]. The %change in HbA1c levels was significantly and negatively correlated with the baseline HbA1c levels (r=-0.51, p<0.001), but not with age, duration of diabetes, or the estimated glomerular filtration rate (eGFR). No patient experienced severe hypoglycemia episodes, and aspartate transaminase, alanine transaminase, gamma-glutamyl transpeptidase, and the eGFR remained unchanged. The dose of sulfonylurea was finally decreased in 72% of patients treated with sulfonylurea. Conclusion Sitagliptin treatment continually decreases the HbA1c level for 24 months and is useful to reduce the dose of sulfonylurea in elderly patients with type 2 diabetes.
Introduction
Diabetes mellitus has become a worldwide social problem because it deteriorates the quality of life and mortality of the patients (1) . The prevalence of type 2 diabetes mellitus is increasing in the elderly population; therefore, how elderly patients with type 2 diabetes are managed remains a very important issue. Previous large scale clinical trials have shown that intensive treatments which lower the HbA1c levels do not improve the mortality of long-established type 2 diabetes (2, 3) . Furthermore, accumulated evidence shows that hypoglycemia increases the risk of cardiovascular disease and mortality (4, 5) . In addition, several studies reported that hypoglycemia may increase cognitive dysfunction (6) and the risk of falling (7, 8) , and the counterregulatory mechanisms are impaired in elderly patients (9) . Therefore, the risk of severe hypoglycemia is increased. Thus, we have to control blood glucose without the risk of hypoglycemia, especially in elderly patients.
The capacity of endogenous insulin secretion is decreased, even in type 2 diabetes (10); therefore, hypoglycemic medication such as sulfonylurea and insulin is frequently used in clinical settings. However, a previous meta-analysis has shown that treatment with sulfonylurea and insulin increase the risk of hypoglycemia (11) . Therefore, treatments with sulfonylurea and insulin should be avoided in elderly patients if possible. On the other hand, dipeptidyl peptidase (DPP)-4 inhibitors have emerged as a new category of oral hypoglycemic agents for type 2 diabetes, which are often used worldwide because DPP-4 inhibitors improve glycemic control without increasing the risk of hypoglycemia. In the present study, we focused on the long-term efficacy and safety of sitagliptin, a DPP-4 inhibitor, in elderly patients with type 2 diabetes and evaluated whether treatment with sitagliptin reduces the rate of sulfonylurea usage.
Materials and Methods

Subjects and data collection
A retrospective study was conducted with 195 patients with type 2 diabetes treated with 50 mg/day sitagliptin. Out of 195 patients, 112 patients were over 65 years of age. In the records of Shimane University Hospital and Matsue City Hospital, the demographic data, clinical characteristics, and current diabetes treatments at the first prescription of sitagliptin were recorded. Hemoglobin A1c (HbA1c), body weight, aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transpeptidase (γGTP), serum creatinine, the estimated glomerular filtration rate (eGFR), prescription, and hypoglycemia episode were recorded for 24 months after the first prescription of sitagliptin. Hypoglycemia was defined as the presence of symptoms suggestive of hypoglycemia, which were confirmed by a self-monitored blood glucose level of <70 mg/dL. Severe hypoglycemia was defined as an episode requiring the assistance of another person or hospitalization. No patient was prescribed any other DPP-4 inhibitors or glucocorticoid, or had hepatitis B or C infection. The numbers of patients who had been taking sulfonylurea, metformin, alpha-glucosidase inhibitors, thiazolidinediones, glinides, and insulin were 120, 95, 55, 28, 9 and 19, respectively. This is a retrospective study based on the record of the hospitals without any intervention. All subjects agreed to participate in the study and provided their verbal informed consent. This study was conducted in compliance with the Declaration of Helsinki and was approved by the Institutional Review Board of the Shimane University Faculty of Medicine.
Statistical analysis
Data are expressed as the mean ± SD. Changes in HbA1c, AST, ALT, γGTP, and the eGFR were examined using a paired Student's t-test. After the baseline laboratory data were transformed to their logarithms, Pearson's correlation coefficient was used in univariate analyses. All analyses were performed using a statistical software program, StatView (Abacus Concepts, Berkeley, USA). A p value <0.05 was considered to be significant.
Results
Efficacy and safety of sitagliptin for 24 months
The baseline characteristics of the subjects are shown in Table 1 . Changes in the HbA1c levels are shown in Figure. The HbA1c levels were significantly decreased during 24 months in not only all subjects (n=195), but also elderly subjects (n=112). The changes in HbA1c were not significantly different between younger and older patients over 65 years of age (data not shown). The %change in HbA1c was significantly and inversely correlated with baseline log (HbA1c) and log (γGTP) in all the subjects (r=-0.46, p< 0.001) and elderly subjects (r=-0.51, p<0.001) ( Table 2 ). The %change in HbA1c was also significantly and inversely correlated with baseline log (ALT) in all the subjects (r= -0.16, p=0.041), but not in elderly subjects.
Liver and kidney functions of elderly subjects were evaluated between baseline and after 24-month treatment with sitagliptin (Table 3) . AST, ALT, γGTP, serum creatinine, and the eGFR were not significantly changed in elderly subjects, while body weight was slightly, but significantly decreased. No patient experienced any severe hypoglycemia episodes during the 24-month period.
Intern Out of 112 elderly patients, 75 had taken sulfonylurea at the start of this study. After 24-month treatment with sitagliptin, the dose of sulfonylurea was decreased in 40 patients (53.3%) and discontinued in 14 patients (18.7%). The dose of sulfonylurea was finally decreased in 72% of the patients treated with sulfonylurea.
Discussion
In this study, treatment with 50 mg/day sitagliptin decreased the HbA1c levels not only in all subjects, but also in elderly patients with type 2 diabetes during 24 months despite decreased sulfonylurea usage. Changes in the HbA1c levels were not correlated with age, duration of diabetes, or the eGFR, although they were inversely correlated with the γGTP levels. After 24 months of treatment with sitagliptin, the liver and kidney functions in elderly patients remained unaltered. In addition, no episode of severe hypoglycemia was recorded. Taken together, these findings indicate that sitagliptin is effective for glycemic control, regardless of the patient's background, and is safe for 24 months even in elderly patients with type 2 diabetes. In addition, sitagliptin treatment might be effective for patients with high levels of γGTP, although the underlying mechanism remains unclear.
As many cases of severe hypoglycemia due to combination therapy of sulfonylurea and DPP-4 inhibitors have been reported, it is recommended that the dose of sulfonylurea should be decreased to avoid hypoglycemia when a DPP-4 inhibitor is added to the regimen in patients treated with higher doses of sulfonylurea. Recently, it was reported that the combination of sulfonylurea and glucagon-like peptide-1, which is an incretin activated by DPP-4 inhibitors, synergistically augments insulin secretion via Epac2aRap1 signaling in pancreatic beta cells (12) . However, it is unclear whether the treatments including DPP-4 inhibitors control the blood glucose levels for a long time when the dose of sulfonylurea is reduced. The present study showed that treatment with 50 mg/day sitagliptin maintained the reduction in HbA1c levels even when the dose of sulfonylurea was reduced in 72% of elderly patients, although information about the reduction dosage of sulfonylurea was not available in this study. Thus, combination therapy of sitagliptin and low-dose sulfonylurea might be beneficial to control blood glucose levels with a decreased risk of severe hypoglycemia in elderly patients with type 2 diabetes.
Sulfonylurea has been shown to cause severe hypoglycemia, particularly in elderly patients because counterregulatory mechanisms are impaired in such patients (9) . Indeed, a previous study has shown that subjective hypoglycemia unawareness is seen in older patients with type 2 diabetes when hypoglycemia at 2.8 mmol/L (50.4 mg/dL) is induced (13) . As severe hypoglycemia causes the risk of cognitive dysfunction and cardiovascular disease, it may be better to replace sulfonylurea with DPP-4 inhibitors in elderly patients. In the present study, sitagliptin treatment decreased the HbA1c levels without severe hypoglycemia in elderly patients. Furthermore, 18.7% of the participants treated with sulfonylurea were able to discontinue it. These findings suggest that DPP-4 inhibitors might improve the risk of diabetic complications as well as hypoglycemia-related adverse events. Therefore, further studies are necessary to clarify whether switching from sulfonylurea to DPP-4 inhibitors improves the quality of life and mortality of elderly patients with type 2 diabetes.
It was previously reported that the glucose-lowering effects of DPP-4 inhibitors are weakened by obesity (14 (15) . DPP-4 is reported to be secreted from adipose tissue (16) ; therefore, the effect of DPP-4 inhibitors might be associated with obesity. However, in the present study, the changes in HbA1c levels were not correlated with body weight or the BMI. Although the reason for the discrepancy between previous reports and ours remains unclear, long-term therapy with sitagliptin may not be associated with obesity in elderly patients.
Conclusion
In this study, 24-month treatment with sitagliptin significantly decreased the HbA1c levels. Moreover, the incidence of severe hypoglycemia was not increased, and the liver and kidney functions were unaltered in elderly patients with type 2 diabetes. The reduction in HbA1c was independent of background data, such as age, duration of diabetes, and body weight. Moreover, replacement from sulfonylurea to sitagliptin may be useful to reduce the risk of sulfonylurearelated severe hypoglycemia in elderly patients. However, this observation must be confirmed in future large-scale longitudinal studies.
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